Internal Medicine, Endocrinology, Diabetes, & Metabolism · Springfield, MA
NPI
1801883194
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2 Medical Center Dr, Suite 210
Springfield, MA, 01107
Phone (413) 734-4667
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
1,965 services
Medicare patients, 2024
409
Average age 75
Drug cost, 2024
$1.9M
6,363 prescriptions
Company payments, 2025
$989
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marc Vanderleeden was code 99213 (office e&m - established), 800 times for 375 patients. In total Marc Vanderleeden billed 1,965 services in 16 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 800 | 375 | $64.42 | $52K |
| 82962 Clinical Chemistry | Office | 451 | 163 | $3.20 | $1,445 |
| 83036 Blood Count | Office | 359 | 155 | $9.52 | $3,418 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 231 | 75 | $42.80 | $9,887 |
| 95251 Test - Miscellaneous | Office | 43 | 21 | $26.77 | $1,151 |
| 99204 Office E&M - New | Office | 35 | 35 | $114.25 | $3,999 |
| 99214 Office E&M - Established | Office | 15 | 15 | $103.09 | $1,546 |
| 93000 Electrocardiogram | Office | 12 | 12 | $11.57 | $139 |
By year: 2022 $62K for 1,512 services; 2023 $73K for 1,852 services; 2024 $75K for 1,965 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 451 | 163 | $3.20 | $1,445 |
| 83036 Blood Count | 359 | 155 | $9.52 | $3,418 |
Medicare prescription drug claims, 2024
In 2024, the drug Marc Vanderleeden prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 530 prescriptions and refills. In total Marc Vanderleeden wrote 6,363 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 530 | 705 | 95 | $732K |
| Levothyroxine Sodium Generic | 431 | 1,210 | 114 | $6,367 |
| Atorvastatin Calcium Generic | 325 | 872 | 89 | $4,227 |
| Jardiance Empagliflozin | 210 | 516 | 57 | $290K |
| Amlodipine Besylate Generic | 196 | 535 | 48 | $1,632 |
| Glipizide Generic | 164 | 418 | 42 | $2,102 |
| Lisinopril Generic | 151 | 422 | 42 | $1,568 |
| Metformin Hcl Generic | 148 | 437 | 50 | $1,553 |
| Simvastatin Generic | 148 | 410 | 39 | $1,083 |
| Lorazepam Generic | 147 | 147 | 29 | $607 |
| Rosuvastatin Calcium Generic | 140 | 395 | 41 | $4,166 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 122 | 258 | 33 | $20K |
| Hydrochlorothiazide Generic | 118 | 351 | 37 | $335 |
| Trulicity Dulaglutide | 118 | 152 | 28 | $146K |
| Omeprazole Generic | 111 | 332 | 35 | $1,769 |
Brand drugs: 1,806 claims; generic drugs: 4,394 claims; opioid claims: 159.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marc Vanderleeden $989 ($989 in general payments such as food, travel and fees) from 18 companies. The largest payer was Novo Nordisk Inc with $195.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 9 | $195 |
| Lilly USA, LLC LLY | 9 | $181 |
| Amgen Inc. AMGN | 5 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| Abbvie Inc. ABBV | 3 | $61.24 |
| Chiesi USA, Inc. | 3 | $58.3 |
| Xeris Pharmaceuticals, Inc. | 2 | $44.97 |
| Dexcom, Inc. DXCM | 1 | $33.08 |
| Antares Pharma, Inc. | 1 | $24.97 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $24.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.